B-CELL MALIGNANCY
Clinical trials for B-CELL MALIGNANCY explained in plain language.
Never miss a new study
Get alerted when new B-CELL MALIGNANCY trials appear
Sign up with your email to follow new studies for B-CELL MALIGNANCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new oral medication called AS-1763 (docirbrutinib) for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe and effective dose and to see how well the drug works agai…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1 • Sponsor: Carna Biosciences, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New pill targets Tough-to-Treat blood cancers in major trial
Disease control Recruiting nowThis study is testing a new oral medication called BGB-16673 for people with various B-cell blood cancers that have come back or stopped responding to prior therapies. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors and controls th…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New hope for tough blood cancers: experimental combo therapy enters human testing
Disease control Recruiting nowThis study is testing whether a new drug called BGB-16673 works better and is safe when combined with other cancer medicines for people with B-cell cancers that have returned or not responded to previous treatments. It will enroll about 80 adults whose cancer has come back or res…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
CRISPR breakthrough: new 'Off-the-Shelf' cell therapy fights tough blood cancers
Disease control Recruiting nowThis study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New 'Off-the-Shelf' cancer treatment trial offers hope for patients who have run out of options
Disease control Recruiting nowThis early-phase study is testing a new type of cell therapy called universal CAR-T (UWD-CD19) for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to standard treatments. The goal is to see if this 'off-the-shelf' therapy, made from donor…
Matched conditions: B-CELL MALIGNANCY
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC